This study is looking at whether an oral medication called Hymecromone can help adolescents and adults with Primary Sclerosing Cholangitis (PSC). PSC is a chronic liver disease that damages the bile ducts. Researchers want to see if taking Hymecromone 400 mg three times a day, along with your usual care, is more effective than just usual care alone. The main way they will measure success is by checking changes in a liver enzyme called gamma-glutamyltransferase (GGT) in your blood over six months. They will also look at other liver markers and signs of inflammation. You may be able to join if you are between 14 and 75 years old and have a confirmed diagnosis of PSC. The study plans to enroll 24 participants, but its current status is unclear.

Study design

This is an interventional study comparing Hymecromone plus standard care to standard care alone. It plans to enroll 24 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured from baseline to Month 6, suggesting a follow-up period of at least six months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.